The Food and Drug Administration approved the design of Anadys Pharmaceuticals Inc.'s (Nasdaq: ANDS) hepatitis C medication ANA598 drug trial sending the stock price soaring $1.11 to $2.91.
FDA Approves Anadys' Drug Trial Design
July 31, 2009 at 13:41 PM EDT
